Peter Strumph, Chief Executive Officer and Director of Nile Therapeutics, Inc., Rings the NASDAQ Closing Bell
July 16, 2008 - Nile Therapeutics, Inc. [NLTX]
About this Marketsite Event:
Peter Strumph, Chief Executive Officer and Director of Nile Therapeutics, Inc., presides over the Closing Bell.
About Nile Therapeutics, Inc.:
Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure; 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties; and CU-NP, a novel rationally designed natriuretic peptide. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio.
For more information about Nile Therapeutics, Inc., please visit www.nilethera.com.
Press Inquiries Only:
Organizations interested in obtaining NASDAQ-listed company bell ringing ceremony photographs for press purposes, must first receive approval from the listed company before requesting photographs from NASDAQ. Please provide the company contact information from whom you received approval to Jolene Libretto at
jolene.libretto@nasdaq.com. Kindly credit © 2008, The Nasdaq Stock Market, Inc. Reprinted with permission.
Other Photography Inquiries:
For all other photography inquiries, please contact NASDAQ’s photographer, Rob Tannenbaum at
rob.tannenbaum@nasdaq.com.
© 2008, The NASDAQ OMX Group, Inc. Reprinted with permission.
